Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate

Objectives Long-term safety and efficacy of adalimumab among patients with juvenile idiopathic arthritis (JIA) was evaluated through 6 years of treatment.Methods Children aged 4–17 years with polyarticular JIA were enrolled in a phase III, randomised-withdrawal, double-blind, placebo-controlled tria...

全面介紹

書目詳細資料

發表在:	RMD Open
Main Authors:	Hermine I Brunner, Carine Wouters, Alberto Martini, Daniel J Lovell, Nicolino Ruperto, Isabelle Kone-Paut, Dirk Elewaut, Ivan Lagunes, Andreas O Reiff, Lawrence Jung, Katerina Jarosova, Dana Němcová, Richard Mouy, Christy Sandborg, John F Bohnsack, Christos Gabriel, Gloria Higgins, Olcay Y Jones, Veronika Vargová, Elizabeth Chalom, Yanna Song
格式:	Article
語言:	英语
出版:	BMJ Publishing Group 2020-09-01
在線閱讀:	https://rmdopen.bmj.com/content/6/2/e001208.full